Profile data is unavailable for this security.
About the company
Hyloris Pharmaceuticals SA is a Belgium-based bio-pharmaceutical company. The Company focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. It has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. It also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.
- Revenue in EUR (TTM)2.81m
- Net income in EUR-15.76m
- Incorporated2017
- Employees24.00
- LocationHyloris Pharmaceuticals SABoulevard Gustave Kleyer 17LIEGE 4000BelgiumBEL
- Phone+32 43460207
- Websitehttps://hyloris.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laboratorio Reig Jofre SA | 323.88m | 8.85m | 251.66m | 1.32k | 27.88 | 1.18 | 11.18 | 0.777 | 0.1115 | 0.1115 | 4.11 | 2.63 | -- | -- | -- | 246,110.20 | -- | 2.14 | -- | 2.79 | 58.04 | 61.39 | 2.73 | 2.65 | 0.8906 | 7.22 | 0.2219 | -- | 16.57 | 11.86 | 16.04 | 0.3019 | -9.54 | -- |
| Genfit SA | 38.18m | -28.89m | 254.30m | 159.00 | -- | 3.74 | -- | 6.66 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Bioventix PLC | 16.01m | 10.21m | 262.81m | 16.00 | 26.19 | 19.51 | 25.39 | 16.41 | 1.63 | 1.63 | 2.56 | 2.19 | 1.09 | 1.53 | 2.54 | 849,780.60 | 69.72 | 56.43 | 79.03 | 61.01 | 93.75 | 92.64 | 63.73 | 65.08 | 6.69 | -- | 0.00 | 84.49 | 9.36 | 7.93 | 9.10 | 8.13 | -37.12 | 20.03 |
| PharmaSGP Holding SE | 107.29m | 18.11m | 266.40m | 89.00 | 14.70 | 5.96 | 9.69 | 2.48 | 1.51 | 1.51 | 8.95 | 3.73 | 0.7818 | 1.06 | 9.12 | 1,205,539.00 | 13.20 | 13.70 | 16.44 | 19.98 | 90.93 | 90.20 | 16.88 | 17.56 | 2.19 | 12.34 | 0.6237 | -- | 17.80 | 10.78 | 37.17 | 2.16 | 25.88 | -- |
| Selvita SA | 78.18m | 15.14m | 269.77m | 387.00 | 17.82 | 3.56 | 10.32 | 3.45 | 3.56 | 3.56 | 18.37 | 17.83 | 0.553 | 9.29 | 4.70 | 398,178.30 | 10.71 | -- | 12.99 | -- | 79.66 | -- | 19.36 | -- | 1.41 | 11.34 | 0.4063 | -- | -3.48 | -- | 130.55 | -- | -- | -- |
| Nanobiotix SA | 30.06m | -39.70m | 277.62m | 102.00 | -- | -- | -- | 9.24 | -1.10 | -1.10 | 0.814 | -0.0391 | 0.3912 | -- | 19.59 | 294,686.30 | -51.67 | -54.11 | -120.56 | -80.68 | -- | -- | -132.08 | -756.15 | -- | -1.98 | 1.04 | -- | -- | 203.88 | 30.40 | -- | -7.81 | -- |
| Natac Natural Ingredients SA | 26.55m | 6.41m | 278.29m | 145.00 | -- | 6.46 | 25.78 | 10.48 | -0.0185 | -0.0185 | 0.0634 | 0.099 | 0.2829 | -0.0095 | 5.02 | 183,137.70 | 6.67 | -- | 8.41 | -- | 100.29 | -- | 23.58 | -- | 0.4491 | -- | 0.5657 | -- | 3,152.85 | -- | 308.68 | -- | -- | -- |
| Allergy Therapeutics plc | 62.73m | -59.14m | 280.69m | 635.00 | -- | 9.01 | -- | 4.47 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
| Hansa Biopharma AB | 14.57m | -74.20m | 285.60m | 166.00 | -- | -- | -- | 19.60 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| Ryvu Therapeutics SA | 12.89m | -21.77m | 294.24m | 230.00 | -- | 6.50 | -- | 22.83 | -4.10 | -4.10 | 2.42 | 8.45 | 0.1302 | 12.39 | 4.99 | 241,760.90 | -21.99 | -21.88 | -24.87 | -25.20 | 56.80 | -6.28 | -168.89 | -284.20 | 4.71 | -- | 0.1193 | -- | 20.32 | -9.50 | -9.94 | -- | 53.71 | -- |
| Hyloris Pharmaceuticals SA | 2.81m | -15.76m | 327.60m | 24.00 | -- | 8.44 | -- | 116.42 | -0.5795 | -0.5795 | 0.1035 | 1.39 | 0.0514 | -- | 0.61 | -- | -28.80 | -22.79 | -32.58 | -28.07 | 96.70 | 93.79 | -560.13 | -640.15 | -- | -- | 0.0432 | -- | 44.23 | 98.64 | -33.92 | -- | 87.74 | -- |
| Kuros Biosciences AG | 34.67m | -14.18m | 343.68m | 80.00 | -- | 5.84 | -- | 9.91 | -0.3697 | -0.3697 | 0.9175 | 1.54 | 0.4347 | 2.40 | 7.27 | 419,550.00 | -17.78 | -13.47 | -21.34 | -14.84 | 71.31 | 78.73 | -40.90 | -81.48 | 1.69 | -84.04 | 0.0364 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| Euroapi SA | 1.02bn | -189.70m | 348.28m | 3.67k | -- | 0.3746 | -- | 0.3418 | -2.01 | -2.01 | 10.73 | 9.78 | 0.6086 | 1.38 | 4.24 | 277,705.10 | -11.34 | -- | -15.93 | -- | 16.15 | -- | -18.63 | -- | 0.6573 | -- | 0.1955 | -- | 3.87 | -- | -1,164.67 | -- | -- | -- |
| Niox Group PLC | 43.34m | 11.19m | 348.60m | 85.00 | 33.02 | 3.27 | 21.29 | 8.04 | 0.0211 | 0.0238 | 0.0819 | 0.2136 | 0.3874 | 2.31 | 6.13 | 432,941.20 | 10.00 | -2.41 | 10.57 | -2.90 | 72.01 | 70.87 | 25.82 | -11.46 | 3.99 | -- | 0.013 | -- | 17.57 | -5.29 | -32.62 | -- | -5.59 | -- |
| Oxford BioMedica plc | 105.46m | -185.49m | 383.37m | 714.00 | -- | 4.26 | -- | 3.64 | -1.63 | -1.63 | 0.9273 | 0.7645 | 0.2513 | 3.91 | 3.07 | 125,404.80 | -51.69 | -19.60 | -64.26 | -24.68 | 44.37 | 50.74 | -205.68 | -44.38 | 2.90 | -22.92 | 0.5888 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
Data as of Apr 26 2024. Currency figures normalised to Hyloris Pharmaceuticals SA's reporting currency: Euro EUR
0.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mandarine Gestion SAas of 29 Feb 2024 | 46.00k | 0.16% |
| Degroof Petercam Asset Management SAas of 31 Jan 2024 | 25.94k | 0.09% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 4.26k | 0.02% |
| Claresco Finance SAas of 30 Jun 2023 | 2.00k | 0.01% |
| DFA Australia Ltd.as of 30 Apr 2024 | 783.00 | 0.00% |
| SSgA Funds Management, Inc.as of 09 May 2024 | 219.00 | 0.00% |
More ▼
Data from 30 Jun 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
